PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)

BACKGROUND: EORTC-1320-BTG investigated the activity, safety and quality of life of therapy with the tetrahydroisoquinoline alkaloid trabectedin (Yondelis(®)) in patients with recurrent higher-grade meningiomas. Trabectedin was originally derived from the Caribbean sea squirt, Ecteinascidia turbinat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Preusser, M, Silvani, A, Le Rhun, E, Soffietti, R, Lombardi, G, Sepulveda, J, Brandal, P, Beaney, R, Bonneville-Levard, A, Lorgis, V, Bromberg, J, Erridge, S, Cameron, A, Marosi, C, Golfinopoulos, V, Gorlia, T, Weller, M, Wick, W
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Oral Presentations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6794943/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.005
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items